Univest
Univest
  • Markets

UPL vs Bayer CropScience India: Which Stock Should You Track

  • August 6, 2026
  • Posted by: Ankit Jaiswal
  • Category: News
No Comments
UPL vs Bayer CropScience India: Which Stock Should You Track

UPL MCap Rs 49,115 Cr, PE 21.14x, ROE 5.54%, D/E 0.68. Bayer CropScience India MCap Rs 19,468 Cr, PE 28.25x, ROE 23.24%, D/E 0.03, Div 3.46%.

UPL vs Bayer CropScience India is a comparison agrochem investors look up when evaluating a large global generic crop protection company against a premium innovation-focused multinational agrochem subsidiary. UPL is an Indian agrochem company that became one of the world’s top 5 crop protection companies through its acquisition of Arysta LifeScience, while Bayer CropScience India is the Indian subsidiary of Bayer AG Germany, selling innovative insecticides, herbicides and fungicides including patented molecules.

This UPL vs Bayer CropScience India article covers reach and market position, key products, latest declared results and stock valuation. The UPL vs Bayer CropScience India data below is sourced from Groww and public company filings and reflects the most recently available information at the time of writing.

Table of Contents

Toggle
  • UPL vs Bayer CropScience India: Reach and Market Position
  • UPL vs Bayer CropScience India: Key Products and Business Mix
  • UPL vs Bayer CropScience India: Latest Results
  • UPL vs Bayer CropScience India: Stock and Valuation
  • UPL vs Bayer CropScience India: Quick Comparison Table
  • Conclusion
  • Frequently Asked Questions
    • What is the main difference between UPL and Bayer CropScience India?
    • Which company has the higher ROE?
    • Which stock trades at a lower P/E?
    • Which stock pays a higher dividend?
    • What was UPL’s Arysta acquisition?
    • What risks apply to agrochem companies?
    • Should I invest in UPL or Bayer CropScience India?

UPL vs Bayer CropScience India: Reach and Market Position

On the UPL side of the UPL vs Bayer CropScience India comparison, UPL sells generic crop protection chemicals, biosolutions and digital ag services across 138 countries after its Arysta acquisition, though it is navigating debt from the acquisition. Market capitalisation is Rs 49,115 Cr.

Click Here – Get Free Investment Predictions

On the Bayer CropScience India side of the UPL vs Bayer CropScience India comparison, Bayer CropScience India sells patented and off-patent crop protection products including Confidor (imidacloprid), Fipronil and Oberon under the Bayer brand in India. Market capitalisation is Rs 19,468 Cr.

UPL vs Bayer CropScience India: Key Products and Business Mix

In the UPL vs Bayer CropScience India product comparison, UPL offers: UPL sells generic fungicides, herbicides, insecticides and biosolutions globally and in India. P/E is 21.14x, ROE 5.54 percent, debt to equity 0.68 from acquisition financing.

For Bayer CropScience India in this UPL vs Bayer CropScience India breakdown: Bayer CropScience sells patented and mature insecticides, herbicides and fungicides in India. P/E is 28.25x, ROE 23.24 percent — high for an agrochem company. Near-zero debt. Dividend yield is 3.46 percent.

UPL vs Bayer CropScience India: Latest Results

The UPL vs Bayer CropScience India results for UPL: UPL has a market cap of Rs 49,115 Cr and P/E of 21.14x. ROE is 5.54 percent, compressed by acquisition-related debt and margin pressure from generic agrochem pricing.

The UPL vs Bayer CropScience India results for Bayer CropScience India: Bayer CropScience India has a market cap of Rs 19,468 Cr and P/E of 28.25x. ROE is 23.24 percent — much higher than UPL — with near-zero debt and a 3.46 percent dividend yield.

Compare UPL and Bayer CropScience India Fundamentals on the Univest Screener

UPL vs Bayer CropScience India: Stock and Valuation

The UPL vs Bayer CropScience India stock comparison uses the latest available market data from Groww. Investors tracking UPL vs Bayer CropScience India should verify current prices on NSE or BSE before trading.

UPL trades at a market cap of Rs 49,115 Cr and P/E of 21.14x with a compressed ROE of 5.54 percent from global expansion debt. Bayer CropScience India trades at Rs 19,468 Cr market cap and P/E of 28.25x with a much higher ROE of 23.24 percent and near-zero debt. Bayer delivers higher capital returns from its innovation-led model.

UPL vs Bayer CropScience India: Quick Comparison Table

The UPL vs Bayer CropScience India comparison table below summarises the key metrics covered in this article side by side.

Parameter UPL Bayer CropScience India
Sector Generic crop protection: global and India Innovation-driven crop protection: India subsidiary
Market Cap Rs 49,115 Cr Rs 19,468 Cr
P/E Ratio 21.14x 28.25x
ROE 5.54% 23.24%
Debt to Equity 0.68 0.03
Dividend Yield 1.03% 3.46%
Business model Generic and biosolutions: 138 countries Patented and off-patent molecules: India market
Parent Shroff family, India-origin global company Bayer AG Germany

Conclusion

The UPL vs Bayer CropScience India comparison above covers the key data points on reach, products, results and valuation. UPL vs Bayer CropScience India offer very different agrochem risk-return profiles. Bayer delivers a high ROE and dividend with near-zero debt and patented molecules. UPL is cheaper but carries acquisition-related debt with compressed current profitability. Investors should review agrochem pricing cycles and debt reduction progress and consult a SEBI-registered advisor before investing.

Download the Univest iOS App or Univest Android App to track UPL and Bayer CropScience India live price and get daily stock recommendations.

Disclaimer: Data and figures in this article are sourced from publicly available information, including company results filings and exchange data, and are current as of the time of writing. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions

What is the main difference between UPL and Bayer CropScience India?

Ans. UPL is a global generic crop protection company selling in 138 countries. Bayer CropScience India sells patented and off-patent insecticides, herbicides and fungicides under Bayer’s global technology brand.

Which company has the higher ROE?

Ans. Bayer CropScience India has an ROE of 23.24 percent, much higher than UPL at 5.54 percent.

Which stock trades at a lower P/E?

Ans. UPL trades at 21.14x trailing earnings, lower than Bayer CropScience at 28.25x.

Which stock pays a higher dividend?

Ans. Bayer CropScience India pays a dividend yield of 3.46 percent, significantly higher than UPL at 1.03 percent.

What was UPL’s Arysta acquisition?

Ans. UPL acquired Arysta LifeScience in 2019 for approximately USD 4.2 billion, becoming one of the world’s top 5 crop protection companies. The acquisition significantly increased UPL’s debt.

What risks apply to agrochem companies?

Ans. Both companies face risk from monsoon-dependent demand, regulatory changes to pesticide approvals, competition from Chinese generic producers and for UPL, debt servicing from its global expansion.

Should I invest in UPL or Bayer CropScience India?

Ans. Bayer has much higher ROE, lower debt and a higher dividend yield. UPL is cheaper but in a de-leveraging phase. Consult a SEBI-registered advisor before investing.



News
Author: Ankit Jaiswal
Ankit Jaiswal is the Senior Research Analyst at Univest, leading the platform's in-house equity research desk and serving as the editorial reviewer for all research and blog content published at univest.in. With 11+ years of experience in Indian equity markets, he oversees stock recommendations, earnings analysis, sector coverage, and ensures every published article meets SEBI Research Analyst Regulations. He holds a Bachelor of Commerce (B.Com) from St. Xavier's College, Kolkata — one of India's most prestigious commerce institutions — and has cleared CMT Level 2 from the CMT Association, a globally recognised certification in technical analysis and market research. His research methodology combines fundamental analysis (earnings quality, balance sheet strength, management commentary) with advanced technical analysis (chart patterns, momentum indicators, market structure) — giving Univest's retail investors a dual-lens approach that most Indian research platforms lack. Ankit is among the most comprehensively certified analysts in Indian financial media, holding five NISM certifications: Series-XV (Research Analyst), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-VI (Depository Operations), and Series-V-A (Mutual Fund Distributors). At Univest — India's SEBI-registered research and advisory platform — Ankit's responsibilities include leading the research team, finalising stock recommendations published across Pro Lite, Pro Super, and Pro Gold advisory services, and maintaining editorial oversight of all YMYL financial content published on the blog.

Leave a Reply Cancel reply